Dr. Venook Discusses the Results of the 80405 Trial

Alan P. Venook, MD
Published Online: Friday, August 15, 2014
Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses results from the CALGB/SWOG 80405 trial of targeted therapies administered in colorectal cancer.

Venook says this trial took 10 years to complete. This study originally set out to find the best first-line treatment for patients with metastatic colorectal cancer. However, the trial ended up focusing only on patients with wild-type KRAS at codons 12 and 13.

The trial enrolled 1137 patients that were randomized between bevacizumab and cetuximab with chemotherapy, Venook says. The results showed a survival of 29.9 months in the cetuximab arms and 29.0 months in the bevacizumab arms.

Online CME Activities
Free CME from PER
Recap of SABCS 2014: Changes for Today and Hope for Tomorrow
Cancer Summaries and Commentaries: Updates From San Francisco in Multiple Myeloma
10th International Symposium on Ovarian Cancer and Gynecologic Malignancies® Medical Crossfire®
Community Practice Connections: 12th Annual International Congress on Targeted Therapies in Cancer®
More Reading
$auto_registration$